NCT Number: NCT00000616
PREMIER: Lifestyle Interventions for Blood Pressure Control
To compare the effectiveness of advice versus two multicomponent lifestyle interventions to control blood pressure in participants with Stage 1 hypertension or higher than optimal blood pressure.
Looking for future studies?
Notify MeKey information
Age range
25 year–100 year
Sex eligibility
All sexes
Study type
Interventional
Phase
Phase 3
About this study
BACKGROUND:
A large body of data has been collected over the years documenting that on the one hand, reduced sodium intake, increased physical activity, weight loss, and moderate alcohol ingestion (Comprehensive Intervention) have been associated with a modest reduction of both systolic and diastolic blood pressure in with high normal and Stage 1 hypertension. On the other hand, the Dietary Approaches to Stop Hypertension (DASH) study has shown that a diet rich in fruits, vegetables, low-fat dairy products, and decreased saturated fat, total fat, and cholesterol (DASH intervention) reduced both diastolic and systolic blood pressure in similar baseline blood pressure groups.
DESIGN NARRATIVE:
A multicenter study to determine the BP-lowering effects of two multi-component lifestyle intervention programs compared with advice only. Eight hundred and ten men and women were randomly assigned to one of three treatment arms: (A) advice only; (B) comprehensive lifestyle intervention, in which participants received an intensive behavioral intervention program to facilitate achieving current lifestyle recommendations for BP control (reduced salt intake, increased physical activity, reduced alcohol intake, and weight control or weight loss if needed); and (C) comprehensive lifestyle intervention plus the DASH diet, in which participants received a behavioral intervention program to promote the DASH dietary pattern in addition to the same lifestyle recommendations for BP control. Participants were followed for 18 months. The primary outcome variable was systolic blood pressure measured at six and 18 months after randomization. Other variables included diastolic blood pressure, dietary adherence, physical activity, and onset of hypertension over the 18 months of follow-up.
The study completion date listed in this record was obtained from the "End Date" entered in the Protocol Registration and Results System (PRS) record.
Who can participate
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Men and women, age 25 and older who were generally healthy except for higher than optimal or mildly elevated blood pressure.
Treatment and study plan
diet, fat-restricted
BehavioralExercise
Behavioraldiet, reducing
Behavioralalcohol drinking
BehavioralSponsors and collaborators
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
Nih
Registry information
Important dates
- Study start
- 1998
- Study completion
- 2004
- First posted
- Oct 28, 1999
- Registry last updated
- Feb 18, 2016
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Related clinical trials
Published trials that share one or more normalized conditions with this study.
Effectiveness of Valsartan Alone vs Combination Therapy in Hypertensive Heart Disease
NCT07544888
Cardiovascular Diseases, Heart Diseases
Lahore, Punjab Province, Pakistan
View Trial DetailsThe HARMONY Study: A Intervention to Reduce Cardiometabolic Risk in African American Women
NCT04705779
Body Weight, Brain Diseases
Chapel Hill, North Carolina, United States
View Trial DetailsBehavior Change Intervention for Cardiovascular Risk Reduction Among People Experiencing Homelessness
NCT06025721
Cardiovascular Diseases, Diabetes Mellitus
Minneapolis, Minnesota, United States
View Trial DetailsCardiac and Immune Cell Function in Preeclampsia
NCT04508582
Cardiovascular Diseases, Cardiovascular Risk Factor
London, United Kingdom
View Trial Details